Bioactive Products
| A unique collection of 51 Anti-platelet aggregation natural compounds | ||
| Catalog No: | B24 | Anti-platelet-aggregation Compound Library Screening Details |
| Size: | 1mg/well * 51 Compounds 2mg/well * 51 Compounds | |
| Cat. No. | Information |
| CFN97337 | Rutaecarpine Rutaecarpine is an inhibitor of COX-2 with an IC50 value of 0.28 μM, and is also a potent inhibitor of CYP1A2. Rutaecarpine has anti-atherosclerosis, immunosuppressive, anti-inflammatory, gastroprotective, vasorelaxing, antihypertensive and anti-platelet effects. Rutaecarpine has positive inotropic and chronotropic effects on the guinea-pig isolated right atria, possible involvement of vanilloid receptors. Rutaecarpine may be useful in the prevention of ultraviolet A-induced photoaging, it inhibits ultraviolet A-induced reactive oxygen species generation, resulting in the enhanced expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human skin cells. |
| CFN97465 | Xanthoxylin Xanthoxyline has antispasmodic, fungistatic, antinociceptive and antioedematogenic activities. Xanthoxylin has inhibitory effect on blood platelet aggregation; it induces melanogenesis mainly via cAMP-mediated PKA activation, other signaling pathways may also play a role in xanthoxylin-induced melanogenesis. |
| CFN97542 | Isoliquiritigenin Isoliquiritigenin has hepatoprotective, chemopreventive, antitumor, vasorelaxant, anti-platelet, anti-allergic, antiviral, antioxidant and anti-inflammatory effects, it can induce growth inhibition and apoptosis through downregulating AA metabolic network and the deactivation of PI3K/Akt in human breast cancer. Isoliquiritigenin also has the ability to protect cells from AA+iron-induced H2O2 production and mitochondrial dysfunction, which is mediated with GSK3β phosphorylation downstream of AMPK. |
| CFN90207 | Glaucocalyxin A Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand. Glaucocalyxin A has regulation of microglia activity, can attenuate lipopolysaccharide -stimulated neuroinflammation through NF-κB and p38 MAPK signaling pathways.Glaucocalyxin A may become a potential anti-fibrotic agent in Idiopathic pulmonary fibrosis (IPF) management, it can effectively ameliorate pulmonary fibrosis through the antagonism of leukocyte infiltration and proinflammatory cytokine production. |
| CFN97551 | Aristolactam AIIIa Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid. |
